- Company
- The standard of Xospata is very disappointing
- by Eo, Yun-Ho May 19, 2022 05:51am
- Insurance benefits for the new leukemia drug Xospata have been applied, but clinics are expressing regret. Acute Myeloid Leukemia (AML) treatment Xospata has been reimbursed since March. Looking at the benefit criteria of this drug, remission-induction therapy is recognized in patients with FLT3 mutant acute myeloid leukemia who are refrac
- Company
- Samsung Bioepis makes ₩199.1 bil in Q1
- by Chon, Seung-Hyun May 19, 2022 05:51am
- Samsung Bioepis is off to a smooth start this year with a sharp rise in its biosimilar sales. According to the Korea Financial Supervisory Service, Samsung Bioepis recorded &8361;199.1 in Q1 sales this year, a 19.4% increase compared to the same quarter of the previous year. Also, the company’s net profit increased 11.5% to &8361;31.9 bill
- Company
- Samsung Bioepis’s Lucentis biosimilar approved in Korea
- by Lee, Seok-Jun May 18, 2022 10:42pm
- Samsung Bioepis became the first company to receive approval for a Lucentis biosimilar in Korea with ‘Amelivu (ranibizumab).’ Lucentis is a treatment developed by Genetech for ophthalmologic diseases such as macular degeneration and macular edema. With Amelivu’s approval, Samsung Bioepis is now approved for a total of 6 biosimilars in Ko
- Company
- Shionogi applies to trademark its COVID-19 treatment
- by Kim, Jin-Gu May 17, 2022 06:02am
- With the domestic trademark application for the COVID-19 treatment that is being jointly developed by Shionogi Pharma and Ildong Pharmaceutical nearing completion, Shionogi Pharma and Ildong Pharmaceutical are speeding up preparations to commercialize its drug in Korea in the second half of this year. According to the Korean Intellectual
- Company
- Pharmaceutical exports fall 19% this year
- by Kim, Jin-Gu May 17, 2022 06:02am
- Pharmaceutical exports from January to April last year were found to have fallen 19% from the same period in the previous year. According to the Korea Customs Service on the 16th, pharmaceutical exports from January to April this year have recorded $2,191,880,000 (approx. &8361;2.81 trillion). This is a 19% decrease from the $2,689,820,000 (
- Company
- Why MSD raised the price of Gardasil 9 for two years?
- by May 17, 2022 06:02am
- As MSD Korea raised the supply price of Gardasil 9, a cervical cancer vaccine, by 25% in two years, attention is being paid to the background. Some interpret the decision ahead of the application of Gadasil 9's health insurance benefits, which was President Yoon Seok-yeol's pledge, or an alternative to fill the sales gap due to the reduction
- Company
- Prescription of CGRP migraine drugs to begin in earnest?
- by Eo, Yun-Ho May 17, 2022 06:01am
- CGRP-targeted migraine treatments are gaining better access as prescriptions. The first drug introduced is nearing insurance benefit listing and the second drug is landing in general hospitals. According to industry sources, the Calcitonin gene-related peptide (CGRP)-targeted migraine treatment ‘Emgality (galcanezumab)’ has passed delib
- Company
- Servier launches supply of new acute leukemia drug Oncaspar
- by Eo, Yun-Ho May 16, 2022 06:14am
- Servier Korea began supplying Oncaspar Lyophilized Inj, a combination treatment for "acute lymphocytic leukemia (ALL)" from the 10th. It was supplied through the rare drug center, but the license holder, Servier, was in charge of the supply, and insurance benefits have not yet been registered. Servier Korea is undergoing prescription procedur
- Company
- Huons' local anesthetics export contract with FPI Canada
- by Kim, Jin-Gu May 16, 2022 06:14am
- Huons announced on the 13th that it has signed an export contract with Canadian pharmaceutical company Formative Pharma Inc (FPI). Items signed an export contract are▲1% Lidocaine hydrochloride injection 5mL, ▲ 0.75% Bupivacaine hydrochloride injection 2ml, and ▲ 1% lidocaine hydrochloride injection 5mL vial. These items were obtained from
- Company
- The introduction of Biogen Aduhelm in Korea is also unclear
- by May 16, 2022 06:13am
- Biogen has decided to minimize the commercialization infrastructure of the Alzheimer's drug Aduhelm and focus on developing subsequent drugs. In fact, it is unclear whether Aduhelm, which is in the process of eviction, will be introduced in Korea. Biogen announced in its first-quarter earnings announcement on the 3rd (local time) that CEO
